Zivo Bioscience - Common Stock, par value $.001 per share (ZIVO)
CUSIP: 98978N101
Q4 2021 13F Holders as of 31 Dec 2021
- Type / Class
- Equity / Common Stock, par value $.001 per share
- Shares outstanding
- 3,908,612
- Total 13F shares
- 82,936
- Share change
- 0
- Total reported value
- $238,000
- Price per share
- $2.87
- Number of holders
- 2
Quarterly Holders Quick Answers
What is CUSIP 98978N101?
CUSIP 98978N101 identifies ZIVO - Zivo Bioscience - Common Stock, par value $.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 98978N101:
Top shareholders of ZIVO - Zivo Bioscience - Common Stock, par value $.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| CREDIT SUISSE AG/ |
13F
|
Company |
—
class O/S missing
|
45,132
|
$206,000 | — | 30 Sep 2021 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
—
class O/S missing
|
41,934
|
$191,000 | — | 30 Sep 2021 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
—
class O/S missing
|
31,367
|
$143,000 | — | 30 Sep 2021 | |
| TWO SIGMA SECURITIES, LLC |
13F
|
Company |
—
class O/S missing
|
30,260
|
$138,000 | — | 30 Sep 2021 | |
| Verdence Capital Advisors LLC |
13F
|
Company |
—
mixed-class rows
|
20,000
mixed-class rows
|
$56,000 | — | 30 Sep 2021 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
—
class O/S missing
|
11,177
|
$51,000 | — | 30 Sep 2021 | |
| Warberg Asset Management LLC |
13F
|
Company |
—
class O/S missing
|
40,000
|
$40,000 | — | 30 Sep 2021 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
—
class O/S missing
|
6,688
|
$30,000 | — | 30 Sep 2021 | |
| CVI Holdings, LLC |
13F
|
Company |
—
class O/S missing
|
16,108
|
$17,000 | — | 30 Sep 2021 | |
| UBS Group AG |
13F
|
Company |
—
mixed-class rows
|
3,410
mixed-class rows
|
$11,000 | — | 30 Sep 2021 | |
| Bartlett & Co. LLC |
13F
|
Company |
—
class O/S missing
|
1,000
|
$5,000 | — | 30 Sep 2021 | |
| BARTLETT & CO. WEALTH MANAGEMENT LLC |
13F
|
Company |
—
class O/S missing
|
1,000
|
$4,560 | — | 30 Sep 2021 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
—
class O/S missing
|
626
|
$3,000 | — | 30 Sep 2021 | |
| MORGAN STANLEY |
13F
|
Company |
—
class O/S missing
|
125
|
$1,000 | — | 30 Sep 2021 | |
| Andrew A. Dahl |
3/4/5
|
President / CEO, Director |
—
class O/S missing
|
376,000
|
— | — | 21 Oct 2021 |
Institutional Holders of Zivo Bioscience - Common Stock, par value $.001 per share (ZIVO) as of Q4 2021
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2021 vs Q2 2021 Across Filers
| Investor | Q2 2021 Shares | Q4 2021 Shares | Share Diff | Share Chg % | Q2 2021 Value $ | Q4 2021 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.